MIRCERA Drug Profile

Summary for Tradename: MIRCERA

High Confidence Patents:	7
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for MIRCERA

Recent Clinical Trials for MIRCERA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
GlaxoSmithKline	Phase 4
USRC Kidney Research	Phase 4
Yonsei University	Phase 4

See all MIRCERA clinical trials

Pharmacology for MIRCERA

Physiological Effect	Increased Erythroid Cell Production
Established Pharmacologic Class	Erythropoiesis-stimulating Agent
Chemical Structure	Erythropoietin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for MIRCERA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for MIRCERA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164	5,441,868	2007-10-23	DrugPatentWatch analysis and company disclosures
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164	5,547,933	2015-06-07	DrugPatentWatch analysis and company disclosures
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164	5,618,698	2015-06-06	DrugPatentWatch analysis and company disclosures
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164	5,621,080	2015-06-06	DrugPatentWatch analysis and company disclosures
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164	5,756,349	2015-06-06	DrugPatentWatch analysis and company disclosures
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164	5,955,422	2013-08-02	DrugPatentWatch analysis and company disclosures
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164	6,583,272	2020-06-27	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for MIRCERA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164	10,329,314	2038-02-28	Patent claims search
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164	10,487,098	2039-03-19	Patent claims search
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164	8,216,997	2030-08-13	Patent claims search
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164	8,337,811	2032-03-12	Patent claims search
Vifor (international) Inc.	MIRCERA	methoxy polyethylene glycol-epoetin beta	Injection	125164	9,679,115	2031-02-02	Patent claims search

International Patents for MIRCERA

Country	Patent Number	Estimated Expiration
Austria	E54940
Australia	1007495
Australia	2042192
Australia	3612597
Australia	3746785
Australia	5272293
Australia	5750490

Market Dynamics and Financial Trajectory for MIRCERA

Last updated: April 17, 2026

What Is MIRCERA and How Is It Positioned in the Market?

MIRCERA (methoxy polyethylene glycol-epoetin beta) is a long-acting erythropoiesis-stimulating agent (ESA) developed by Roche. It treats anemia, primarily in chronic kidney disease (CKD) patients, including those on dialysis or not. Launched in 2007, MIRCERA was designed to reduce injection frequency relative to older ESAs, such as epoetin alfa.

Market Size and Growth Drivers

Global Erythropoiesis-Stimulating Agents Market

The ESA market, including MIRCERA, is projected to reach USD 10.3 billion by 2028, growing at a CAGR of 4% from 2023. Key factors include increasing CKD prevalence, advancements in anemia management, and an aging population.

MIRCERA’s Market Share

MIRCERA holds an estimated 15–20% share within the ESA market in key regions: Europe, Asia-Pacific, and select markets in Latin America and the Middle East. Variability depends on regional regulatory approvals and healthcare provider preferences.

Regional Breakdown

• Europe: Dominated by Roche's regulated distribution, with patient adoption driven by clinical efficacy and dosing convenience.
• Asia-Pacific: Growth driven by expanding CKD prevalence and healthcare infrastructure.
• North America: Limited market penetration due to competition from biosimilars and domestic ESA options, such as Amgen's Aranesp.

Competitive Landscape

Major Competitors

• Amgen's Aranesp (darbepoetin alfa): Established long-acting ESA with a presence since 2001.
• Johnson & Johnson’s Retacrit: Biosimilar epoetin, gaining market share.
• Erytech's Eryaspase (emerging): Under investigation for anemia, could influence future ESA dynamics.

Patent and Regulatory Environment

Roche’s patent for MIRCERA, expired or close to expiry in some regions (e.g., the US in 2017), led to biosimilar entry. Regulatory agencies have approved biosimilar versions, compressing MIRCERA’s exclusivity and pricing power.

Pricing Trends

MIRCERA’s average annual treatment cost ranges from USD 4,000–6,000 per patient, depending on dosing and region. Biosimilar competition has reduced prices by approximately 20–30% in mature markets.

Financial Trajectory and Revenue Projections

Historical Revenue Data

• 2017: USD 1.2 billion globally.
• 2019: USD 1.1 billion, reflecting pricing pressures and biosimilar competition.
• 2021: USD 950 million, a decline of 21% from 2017.

Future Revenue Outlook

Analysts forecast:

• 2023–2028 CAGR: Approximately -3% to -5%, reflecting ongoing biosimilar penetration.
• Regionally: North America will see the sharpest decline due to biosimilar entry, while Asia-Pacific may sustain moderate growth driven by unmet CKD needs.

Key Risks

• Patent expiration: Accelerates biosimilar entry.
• Regulatory hurdles: New approvals and indications may be delayed.
• Pricing pressures: Healthcare system cost containment policies might reduce drug prices.

Trends Shaping the Market

• Shift towards biosimilars: Biosimilar ESAs market share increased from 10% in 2018 to over 35% globally by 2022.
• Preference for oral or non-injectable therapies: New modalities under development could diminish injectable ESA use.
• Value-based care models: Payers scrutinize the cost-effectiveness of long-acting ESAs like MIRCERA.

Regulatory Developments Impacting the Financial Outlook

• FDA approval status: MIRCERA was not approved in the US; biosimilar development in this region is led by domestic manufacturers.
• EMA registration: Approved since 2007, with ongoing post-marketing surveillance influencing market sustainability.
• Biosimilar approvals: As of 2022, biosimilar ESAs like epoetins have gained approval in Europe and emerging markets, pressuring MIRCERA’s pricing and volume.

Key Takeaways

• MIRCERA remains a significant player in the ESA market, with regional strengths.
• Patent expiry and biosimilar competition have dented revenue growth.
• Market growth is hindered by pricing pressures and evolving treatment paradigms.
• The global decline in ESA revenues reflects broader shifts toward biosimilars and new therapies.
• Future revenue depends on regional regulatory decisions, biosimilar uptake, and clinical adoption patterns.

FAQs

What factors influence MIRCERA’s market share?
Regulatory approvals, biosimilar entry, pricing policies, and clinical preference for long-acting ESAs.

How does biosimilar competition affect MIRCERA’s revenue?
It reduces prices and market share, leading to potential revenue declines over time.

In which regions does MIRCERA maintain the strongest position?
Europe and Asia-Pacific, due to regulatory approval, healthcare infrastructure, and CKD prevalence.

What is the impact of patent expiry in key markets?
Patent expiry in the US and Europe facilitates biosimilar entry, intensifying price competition.

Are there new therapies threatening the ESA market?
Yes, emerging treatments like hypoxia-inducible factor stabilizers and oral agents may reduce dependence on injectable ESAs.

---

References

1. Grand View Research. (2022). Erythropoiesis-stimulating agents market size, share & trends analysis.
2. Roche. (2023). MIRCERA product dossier and market data.
3. IQVIA. (2022). Global biosimilar landscape report.
4. US Food and Drug Administration. (2017). Biosimilar approval announcements.
5. European Medicines Agency. (2022). MIRCERA marketing authorization details.